ReviewCurrent opinion in urology2010
Prostate-specific antigen screening: pro.
Review in Current opinion in urology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 3 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- High-intensity interval training versus moderate-intensity continuous training for localized prostate cancer under active surveillance: a systematic review and network meta-analysis.Prostate cancer and prostatic diseases · 2025Pooled it
- Effect of high-intensity interval training on aerobic capacity and fatigue among patients with prostate cancer: a meta-analysis.World journal of surgical oncology · 2022Pooled it
- Prostate cancer screening with prostate-specific antigen (PSA) test: a clinical practice guideline.BMJ (Clinical research ed.) · 2018Guideline
- Cumulative Effect Assessment of Common Genetic Variants on Prostate Cancer: Preliminary Studies.Biomedicines · 2022Article
- Genetic variant located on chromosome 17p12 contributes to prostate cancer onset and biochemical recurrence.Scientific reports · 2022Article
- Targeting Splicing in Prostate Cancer.International journal of molecular sciences · 2018Review
- Determining optimal prostate-specific antigen thresholds to identify an increased 4-year risk of prostate cancer development: an analysis within the Veterans Affairs Health Care System.World journal of urology · 2016Article
- Prostate cancer risk after anti-androgen treatment for priapism.International urology and nephrology · 2014Article
- The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4-10 ng/mL.International urology and nephrology · 2014Article
- Metabolomic imaging of prostate cancer with magnetic resonance spectroscopy and mass spectrometry.European journal of nuclear medicine and molecular imaging · 2013Review
- Epidemiology of prostate cancer in the Asia-Pacific region.Prostate international · 2013Review
- Nuclear MTA1 overexpression is associated with aggressive prostate cancer, recurrence and metastasis in African Americans.Scientific reports · 2013Article
- The expression level of lysophosphatidylcholine acyltransferase 1 (LPCAT1) correlates to the progression of prostate cancer.Experimental and molecular pathology · 2012Article
- Prostate cancer: a presentation of clinicopathologic prognosticators among Filipino and American men at radical prostatectomy.Asian journal of andrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewProstate cancer is the most common noncutaneous malignancy among men in the USA and is most frequently diagnosed through prostate-specific antigen (PSA)-based screening. Nevertheless, PSA testing has become increasingly controversial. In this review, we will present the evidence supporting the role of PSA in prostate cancer screening. RECENT
findingsNumerous studies have shown that the risk of current and future prostate cancer is directly related to the serum PSA level. Moreover, increasing PSA levels predict a greater risk of adverse pathologic features and worse disease-specific survival. Substantial epidemiologic evidence has suggested a reduction in advanced disease and improvements in prostate cancer survival rates since the introduction of PSA-based screening. Recently, evidence from a randomized trial further validated that PSA testing reduces both metastatic disease and prostate cancer-specific mortality. SUMMARY: PSA is a valid marker for prostate cancer and its aggressiveness. Level 1 evidence is now available that PSA-based screening reduces both the rate of metastatic disease and prostate cancer-specific mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.